Table 1.
Cohort demographics among those with and without phenytoin‐induced cutaneous adverse events
| With cutaneous adverse event | Without cutaneous adverse event | P value | |
|---|---|---|---|
| Total | 32 | 350 | |
| Sex, n (%) | |||
| Female | 18 (56%) | 170 (49%) | 0.41 |
| Male | 14 (44%) | 180 (51%) | |
| Age at first fill | |||
| < 60 | 7 (22%) | 75 (21%) | 0.61 |
| 61–80 | 19 (6%) | 182 (52%) | |
| 81+ | 6 (19%) | 93 (27%) | |
| Race/ethnicity, n (%) | |||
| Asian | < 5 | < 5 | 0.11 |
| Black | < 5 | < 5 | |
| White, Hispanic | < 5 | < 5 | |
| White, non‐Hispanic | 24 (75%) | 284 (81%) | |
| CYP2C9 metabolizer genotype, n (%) | |||
| Extensive | 18 (56%) | 246 (70%) | 0.02 |
| High‐intermediate | 6 (19%) | 71 (20%) | |
| Low‐intermediate/poor | 8 (25%) | 33 (9%) | |
| CYP2C19 metabolizer genotype, n (%) | |||
| Rapid or ultra‐rapid | 5 (16%) | 107 (31%) | 0.21 |
| Extensive | 15 (47%) | 133 (38%) | |
| Intermediate or Poor | 12 (38%) | 109 (31%) | |
May not add to 100% due to rounding; cells with low counts are masked for participant privacy. Pearson’s χ2 test was used for statistical comparisons between each group, except for comparing the distribution of race/ethnicity, where Fisher’s exact test was used due to low cell counts.
CYP, cytochrome P450.